公开(公告)号：US08178513B2

公开(公告)日：2012-05-15

申请号：US12480391

申请日：2009-06-08

Applicant: Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voigt ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy X. H. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter

Inventor： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voigt ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy X. H. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter

IPC: A01N57/00 ,  A01N43/54 ,  A01N43/40 ,  A61K31/675 ,  A61K31/44 ,  A61K31/445 ,  C07D239/02 ,  C07D233/00 ,  C07D239/24 ,  C07D401/00

CPC classification number: C07D233/88 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/655 ,  A61K45/06 ,  C07D233/46 ,  C07D233/70 ,  C07D235/02 ,  C07D239/22 ,  C07D239/70 ,  C07D271/07 ,  C07D273/00 ,  C07D295/15 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/08 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D407/06 ,  C07D409/04 ,  C07D409/06 ,  C07D409/10 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/06 ,  Y02A50/411

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, U, X, R1, R2, R3, and R4 are as defined herein, and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of using such compounds to inhibit aspartyl protease and to treat a variety of disease or disorders, including cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist

Abstract translation: 公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂化物，其中W，U，X，R 1，R 2，R 3和R 4如本文所定义，并且药物组合物包含式I化合物 还公开了使用这些化合物抑制天冬氨酰蛋白酶和治疗各种疾病或病症（包括心血管疾病，认知和神经变性疾病）的方法。 还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱拮抗剂组合治疗认知或神经变性疾病的方法

公开(公告)号：US08168641B2

公开(公告)日：2012-05-01

申请号：US11759336

申请日：2007-06-07

Applicant: Yusheng Wu ,  Ulrich Iserloh ,  Jared N. Cumming ,  Xiaoxiang Liu ,  Robert D. Mazzola ,  Zhong-Yue Sun ,  Ying Huang ,  Andrew Stamford ,  Brian McKittrick ,  Zhaoning Zhu

Inventor： Yusheng Wu ,  Ulrich Iserloh ,  Jared N. Cumming ,  Xiaoxiang Liu ,  Robert D. Mazzola ,  Zhong-Yue Sun ,  Ying Huang ,  Andrew Stamford ,  Brian McKittrick ,  Zhaoning Zhu

IPC: C07D239/20 ,  C07D239/22 ,  A61K31/497 ,  A61K31/513 ,  A61K31/506 ,  A61P9/00 ,  A61P25/28 ,  A61P31/18 ,  C07D495/20 ,  A61K31/527

CPC classification number: C07D239/20 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D405/04 ,  C07D409/14 ,  C07D411/04 ,  C07D417/04 ,  C07D417/14 ,  C07D495/20

Abstract: Disclosed are compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R1, R2, R6, R7, R30 and R31 are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract translation: 公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂合物，U，W，X，R 1，R 2，R 6，R 7，R 30和R 31如上文在说明书中所述。 还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经变性疾病的方法。 还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱m1激动剂或m2拮抗剂组合治疗认知或神经变性疾病的方法。

公开(公告)号：US20110009392A1

公开(公告)日：2011-01-13

申请号：US12671806

申请日：2008-08-04

Applicant: Zhaoning Zhu ,  William J. Greenlee ,  John P. Caldwell ,  Robert D. Mazzola, JR. ,  Brian McKittrick ,  Chad E. Bennett ,  Xianhai Huang ,  Hubert B. Josien ,  Duane A. Burnett

Inventor： Zhaoning Zhu ,  William J. Greenlee ,  John P. Caldwell ,  Robert D. Mazzola, JR. ,  Brian McKittrick ,  Chad E. Bennett ,  Xianhai Huang ,  Hubert B. Josien ,  Duane A. Burnett

IPC: A61K31/55 ,  C07D487/04 ,  C07D235/02 ,  C07D498/04 ,  C07D491/04 ,  A61K31/4188 ,  A61K31/519 ,  A61K31/535 ,  A61K31/4353 ,  A61K31/435 ,  A61K31/47 ,  A61K31/505 ,  A61K31/397 ,  A61K31/4406 ,  A61K38/16 ,  A61P25/28

CPC classification number: C07D487/04 ,  C07D217/24 ,  C07D498/04

Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

公开(公告)号：US10329289B2

公开(公告)日：2019-06-25

申请号：US15386009

申请日：2016-12-21

Applicant: Jianming Bao ,  Xiaolei Gao ,  Sandra L. Knowles ,  Chunsing Li ,  Michael Man-Chu Lo ,  Robert D. Mazzola, Jr. ,  Debra L. Ondeyka ,  Andrew W. Stamford ,  Fengqi Zhang

Inventor： Jianming Bao ,  Xiaolei Gao ,  Sandra L. Knowles ,  Chunsing Li ,  Michael Man-Chu Lo ,  Robert D. Mazzola, Jr. ,  Debra L. Ondeyka ,  Andrew W. Stamford ,  Fengqi Zhang

IPC: C07D471/04 ,  C07F9/22 ,  C07D519/00 ,  C07D491/048 ,  C07D471/08 ,  C07D491/052 ,  A61K31/437 ,  A61P25/00

Abstract: The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

公开(公告)号：US20140378416A1

公开(公告)日：2014-12-25

申请号：US14345114

申请日：2012-09-11

Applicant: Michael P. Dwyer ,  Kartik M. Keertikar ,  Qingbei Zeng ,  Robert D. Mazzola, JR. ,  Wensheng Yu ,  Haiqun Tang ,  Seong Heon Kim ,  Ling Tong ,  Stuart B. Rosenblum ,  Joseph A. Kozlowski ,  Anilkumar Gopinadhan Nair

Inventor： Michael P. Dwyer ,  Kartik M. Keertikar ,  Qingbei Zeng ,  Robert D. Mazzola, JR. ,  Wensheng Yu ,  Haiqun Tang ,  Seong Heon Kim ,  Ling Tong ,  Stuart B. Rosenblum ,  Joseph A. Kozlowski ,  Anilkumar Gopinadhan Nair

IPC: C07F7/10 ,  A61K45/06 ,  A61K31/695

CPC classification number: C07F7/10 ,  A61K31/695 ,  A61K45/06 ,  A61K2201/094 ,  A61K2300/00 ,  C07F7/0816

Abstract: The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

Abstract translation: 本发明涉及式（I）的新的含甲硅烷基的杂环化合物及其药学上可接受的盐，其中A，B，C，D，E，F和L如本文所定义。 本发明还涉及包含至少一种含甲硅烷基的杂环化合物的组合物，以及使用含有甲硅烷基的杂环化合物治疗或预防患者HCV感染的方法。

公开(公告)号：US08691831B2

公开(公告)日：2014-04-08

申请号：US13416140

申请日：2012-03-09

Applicant: Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voight ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John P. Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoxiang Liu ,  Tao Guo ,  Thuy X. E. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey A. Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

Inventor： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voight ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John P. Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoxiang Liu ,  Tao Guo ,  Thuy X. E. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey A. Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

IPC: A01N43/54 ,  A61K31/505

CPC classification number: C07D233/88 ,  A61K31/4168 ,  A61K31/4178 ,  C07D239/22 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D417/10 ,  C07D417/14 ,  C07D495/10

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula I are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract translation: 公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂化物，其中式I中的每个变量如说明书中所定义; 以及包含式I化合物的药物组合物。还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经退行性疾病的方法，以及抑制人类免疫缺陷病毒，plasmepins，组织蛋白酶D和 原生动物酶。 还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱m1激动剂或m2拮抗剂组合治疗认知或神经变性疾病的方法。

公开(公告)号：US20110053918A1

公开(公告)日：2011-03-03

申请号：US12665551

申请日：2008-06-27

Applicant: Zhaoning Zhu ,  William J. Greenlee ,  Robert D. Mazzola, JR. ,  Jun Qin ,  Xianhai Huang ,  Anandan Palani

Inventor： Zhaoning Zhu ,  William J. Greenlee ,  Robert D. Mazzola, JR. ,  Jun Qin ,  Xianhai Huang ,  Anandan Palani

IPC: A61K31/541 ,  C07D239/70 ,  C07D239/24 ,  C07D233/56 ,  C07D403/12 ,  C07D401/10 ,  C07D279/02 ,  C07D413/10 ,  C07D265/36 ,  C07D241/36 ,  A61K31/4353 ,  A61K31/519 ,  A61K31/505 ,  A61K31/4166 ,  A61K31/4439 ,  A61K31/5355 ,  A61K31/538 ,  A61K31/497 ,  A61P25/28 ,  A61P9/10 ,  A61P25/00

CPC classification number: C07D487/04 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10 ,  C07D417/10 ,  C07D471/04

Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

公开(公告)号：US07652020B2

公开(公告)日：2010-01-26

申请号：US11142601

申请日：2005-06-01

Applicant: Zhuyan Guo ,  Peter Orth ,  Zhaoning Zhu ,  Robert D. Mazzola ,  Tin-Yau Chan ,  Henry A. Vaccaro ,  Brian McKittrick ,  Joseph A. Kozlowski ,  Brian J. Lavey ,  Guowei Zhou ,  Sunil Paliwal ,  Shing-Chun Wong ,  Neng-Yang Shih ,  Pauline C. Ting ,  Kristin E. Rosner ,  Gerald W. Shipps, Jr. ,  M. Arshad Siddiqui ,  David B. Belanger ,  Chaoyang Dai ,  Dansu Li ,  Vinay M. Girijavallabhan ,  Janeta Popovici-Muller ,  Wensheng Yu ,  Lianyun Zhao

Inventor： Zhuyan Guo ,  Peter Orth ,  Zhaoning Zhu ,  Robert D. Mazzola ,  Tin-Yau Chan ,  Henry A. Vaccaro ,  Brian McKittrick ,  Joseph A. Kozlowski ,  Brian J. Lavey ,  Guowei Zhou ,  Sunil Paliwal ,  Shing-Chun Wong ,  Neng-Yang Shih ,  Pauline C. Ting ,  Kristin E. Rosner ,  Gerald W. Shipps, Jr. ,  M. Arshad Siddiqui ,  David B. Belanger ,  Chaoyang Dai ,  Dansu Li ,  Vinay M. Girijavallabhan ,  Janeta Popovici-Muller ,  Wensheng Yu ,  Lianyun Zhao

IPC: A61K31/519 ,  A61K31/506 ,  A61K31/4709 ,  A61K31/43 ,  A61K31/4245 ,  C07D413/00 ,  C07D241/36 ,  C07D471/00 ,  C07D295/00 ,  C07D471/02 ,  C07D401/00 ,  C07D513/00 ,  C07D277/22 ,  C07D277/62 ,  C07D263/30 ,  C07D261/06 ,  C07D235/00 ,  C07D209/04 ,  C07D207/00 ,  C07D205/00 ,  C07D409/00 ,  C07D307/00

CPC classification number: C07D409/14 ,  C07C235/06 ,  C07C235/08 ,  C07C235/10 ,  C07C2601/08 ,  C07D207/20 ,  C07D207/26 ,  C07D209/44 ,  C07D215/14 ,  C07D217/06 ,  C07D263/32 ,  C07D295/185 ,  C07D307/52 ,  C07D333/20 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D513/04

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-α or combinations thereof.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，溶剂合物或异构体，其可用于治疗由MMP，ADAM，TACE，TNF-α或其组合介导的疾病或病症。

公开(公告)号：US20190315762A1

公开(公告)日：2019-10-17

申请号：US16471675

申请日：2017-12-18

Applicant: Xiaolei GAO ,  Sandra L. KNOWLES ,  Chun-sing LI ,  Michael Man-Chu LO ,  Robert D. MAZZOLA, JR. ,  Ling TONG ,  Merck Sharp & Dohme Corp.

Inventor： Xiaolei GAO ,  Sandra L. KNOWLES ,  Chunsing LI ,  Michael Man-Chu LO ,  Robert D. MAZZOLA, Jr. ,  Ling TONG

IPC: C07D491/052 ,  C07D471/04 ,  C07D498/04 ,  C07D491/048

Abstract: The present invention is directed to 6,6-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

公开(公告)号：US08829036B2

公开(公告)日：2014-09-09

申请号：US13420007

申请日：2012-03-14

Applicant: Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voight ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John P. Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoiang Liu ,  Tao Guo ,  Thuy X. E. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey A. Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

Inventor： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voight ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John P. Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoiang Liu ,  Tao Guo ,  Thuy X. E. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey A. Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

IPC: A61K31/4168 ,  A61K31/4178 ,  C07D403/06 ,  C07D233/88

CPC classification number: C07D233/88 ,  A61K31/4168 ,  A61K31/4178 ,  C07D239/22 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D417/10 ,  C07D417/14 ,  C07D495/10

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.